FATE•benzinga•
Fate Therapeutics Presents 6-Month Follow-Up Data On First Patient Treated In Phase 1 Autoimmunity Study With Fludarabine-Free Conditioning And FT819 Off-The-Shelf, 1XX CAR T-Cell Product Candidate At ACR Convergence
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 18, 2024 by benzinga